Galapagos CEO Onno van de Stolpe calls the development deal with Abbott Laboratories (ABT) announced earlier today the "largest Phase 2 deal in the history of the industry." The agreement will line up Abbott in competition with Pfizer (PFE) in a race to develop a widely used rheumatoid arthritis drug. Shares of Galapagos are up 22% in Brussels trading